Profund Advisors LLC Has $630,000 Holdings in Becton, Dickinson and Company $BDX

Profund Advisors LLC decreased its stake in Becton, Dickinson and Company (NYSE:BDX) by 6.8% during the 2nd quarter, HoldingsChannel reports. The fund owned 3,659 shares of the medical instruments supplier’s stock after selling 267 shares during the period. Profund Advisors LLC’s holdings in Becton, Dickinson and Company were worth $630,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of BDX. First Eagle Investment Management LLC grew its position in Becton, Dickinson and Company by 59.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after purchasing an additional 3,268,478 shares during the last quarter. GQG Partners LLC bought a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $689,833,000. Vanguard Group Inc. lifted its stake in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after buying an additional 1,259,750 shares during the period. Nuveen LLC bought a new position in Becton, Dickinson and Company during the first quarter valued at about $211,097,000. Finally, Kingstone Capital Partners Texas LLC bought a new position in Becton, Dickinson and Company during the second quarter valued at about $155,080,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $192.03 on Thursday. The firm has a market capitalization of $55.04 billion, a P/E ratio of 34.54, a P/E/G ratio of 1.42 and a beta of 0.25. The stock has a fifty day moving average price of $186.61 and a two-hundred day moving average price of $181.95. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion for the quarter. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be issued a dividend of $1.05 per share. The ex-dividend date of this dividend is Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Piper Sandler decreased their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Jefferies Financial Group reduced their target price on Becton, Dickinson and Company from $257.00 to $215.00 in a research report on Friday, November 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Wells Fargo & Company increased their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Finally, Morgan Stanley raised their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $203.27.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,249 shares of company stock worth $231,358 over the last three months. 0.36% of the stock is owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.